The right dose is the lowest effective dose that achieves your goal with minimal side effects
Preclinical Safety Evaluation In preclinical studies, BPC 157 did not lead to any serious toxicity in tested animals, including: mice rats rabbits dogs These studies provide a strong foundation for understanding the safety profile of BPC 157, indicating that it is well-tolerated across different species
In astudyinvolving rats, BPC-157 was administered in doses of 0, 0.1, 0.25, and 0.5 micrograms/mL over 24 hours. Results showed that the 0.5 microgram/mL dose significantly increased growth hormone expression from day 1 to day 3, while lower doses also had similar effects. The study concluded that BPC-157 supplementation led to increased up-regulation of growth hormone in a dose and time-dependent manner
Despite these hurdles, the study highlights BPC 157 as a highly promising but still experimental therapy that requires more research, especially in humans, before it can be widely recommended for medical use